Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256975 | 0.85 | AKR1B1 (0.39) | AKR1B1AKR1A1MMP2MMP3MMP8 | |
| SCHEMBL4260042 | 0.83 | CNR1 (0.43) | PTGDR2ALDH1A1AKR1B1AKR1A1MAPT | |
| SCHEMBL4253008 | 0.82 | AKR1B1 (0.39) | PTGDR2AKR1B1AKR1A1MMP2MMP3 | |
| SCHEMBL4161031 | 0.81 | CNR1 (0.46) | PTGDR2ALDH1A1ALDH2AKR1B1AKR1A1 | |
| SCHEMBL4255513 | 0.78 | PTGDR2 (0.40) | PTGDR2ALDH1A1ALDH2AKR1B1RCE1 | |
| SCHEMBL4254387 | 0.76 | CNR1 (0.42) | AKR1B1AKR1A1MMP2MMP3MMP8 | |
| SCHEMBL4261580 | 0.76 | AKR1B1 (0.44) | PTGDR2ALDH1A1ALDH2AKR1B1AKR1A1 | |
| SCHEMBL4163352 | 0.76 | AKR1B1 (0.38) | ALDH1A1AKR1B1AKR1A1MMP2MMP3 | |
| SCHEMBL23390595 | 0.75 | AKR1A1 (0.39) | ALDH1A1AKR1B1AKR1A1MAPTHSD17B10 | |
| SCHEMBL4178111 | 0.75 | AKR1B1 (0.39) | PTGDR2ALDH1A1AKR1B1AKR1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | PTGDR2 193/4885ALDH1A1 502/4885ALDH2 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.